NO20091486L - Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7 - Google Patents

Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7

Info

Publication number
NO20091486L
NO20091486L NO20091486A NO20091486A NO20091486L NO 20091486 L NO20091486 L NO 20091486L NO 20091486 A NO20091486 A NO 20091486A NO 20091486 A NO20091486 A NO 20091486A NO 20091486 L NO20091486 L NO 20091486L
Authority
NO
Norway
Prior art keywords
alkyl
protein kinase
kinase inhibitors
hal
drugs
Prior art date
Application number
NO20091486A
Other languages
English (en)
Inventor
Vincent Leroy
Eric Bacque
Emmanuel Conseille
Anke Steinmetz
Baptiste Ronan
Jean-Philippe Letallec
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20091486L publication Critical patent/NO20091486L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel (1) der: X-Y er NH-C(S), N=C-NR7R8, N=C-SR, N=C-R eller N=C-OR; R og R1 er H eller eventuelt substituert cykloalkyl, alkyl, heterocykloalkyl, aryl eller heteroaryl; R2 er H, Hal eller alkyl; R3 er H, Hal, OH, alkyl eller alkoksy; R4 er H, Hal, CN eller alkyl; R5 er i det vesentlige H, Hal, OH, NR7R8, cykloalkyl, alkyl, alkoksy, heterocykloalkyl, aryl eller heteroaryl, eventuelt substituert; R6 er H, Hal, OH, NI-12, Nhalk,N(alk)2, alkyl eller alkoksy; eller der R7 og R8 slik at en H er eventuelt substituert alk, mens den andre er H eller eventuelt substituert cykloalkyl, alkyl, heterocykloalkyl, heteroaryl eller aryl; eller med R7 og R8 sammen med N danner en eventuelt cyklisk rest som eventuelt inneholder O, S eller N. Det beskrives videre isomerer og salter derav, mer anvendt som medikament og i det vesentlige som proteinkinaseinhibitorer, særlig CDC7. (Henviser til fig. 1).
NO20091486A 2006-10-12 2009-04-16 Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7 NO20091486L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608924A FR2907120B1 (fr) 2006-10-12 2006-10-12 Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
PCT/FR2007/001651 WO2008046982A2 (fr) 2006-10-12 2007-10-10 Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7

Publications (1)

Publication Number Publication Date
NO20091486L true NO20091486L (no) 2009-04-16

Family

ID=37964098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091486A NO20091486L (no) 2006-10-12 2009-04-16 Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7

Country Status (29)

Country Link
US (1) US8314121B2 (no)
EP (1) EP2094699B1 (no)
JP (1) JP2010505922A (no)
KR (1) KR101552361B1 (no)
CN (1) CN101522678A (no)
AR (1) AR063249A1 (no)
AT (1) ATE517105T1 (no)
AU (1) AU2007311833B2 (no)
BR (1) BRPI0719790A2 (no)
CA (1) CA2660166C (no)
CL (1) CL2007002934A1 (no)
CO (1) CO6160310A2 (no)
CY (1) CY1112066T1 (no)
DK (1) DK2094699T3 (no)
EA (1) EA018496B1 (no)
ES (1) ES2370049T3 (no)
FR (1) FR2907120B1 (no)
HR (1) HRP20110759T1 (no)
IL (1) IL197452A (no)
MA (1) MA30877B1 (no)
MX (1) MX2009003283A (no)
NO (1) NO20091486L (no)
PL (1) PL2094699T3 (no)
PT (1) PT2094699E (no)
RS (1) RS51985B (no)
SI (1) SI2094699T1 (no)
TW (1) TW200821310A (no)
UY (1) UY30642A1 (no)
WO (1) WO2008046982A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120024619A (ko) 2009-04-20 2012-03-14 에스비아이 바이오테크 가부시키가이샤 티아졸리디논 유도체
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
CA2795422A1 (en) * 2010-04-19 2011-10-27 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
DK2692728T3 (en) * 2011-03-31 2018-10-08 Carna Biosciences Inc UNKNOWN FURANONDERIVATE
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
EP3856352A4 (en) 2018-09-24 2022-06-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
KR102491260B1 (ko) * 2019-12-26 2023-01-27 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
JP4787150B2 (ja) 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Jnk阻害剤
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Rock 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
PL1805175T3 (pl) * 2004-10-14 2008-08-29 Hoffmann La Roche Nowe azaindolotiazolinony jako środki przeciwrakowe
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
CY1112066T1 (el) 2015-11-04
EP2094699A2 (fr) 2009-09-02
EA018496B1 (ru) 2013-08-30
MA30877B1 (fr) 2009-11-02
WO2008046982A2 (fr) 2008-04-24
ES2370049T3 (es) 2011-12-12
CN101522678A (zh) 2009-09-02
AR063249A1 (es) 2009-01-14
EA200970364A1 (ru) 2009-10-30
IL197452A (en) 2015-10-29
US20090253679A1 (en) 2009-10-08
CA2660166C (fr) 2015-12-29
IL197452A0 (en) 2009-12-24
KR101552361B1 (ko) 2015-09-10
ATE517105T1 (de) 2011-08-15
FR2907120B1 (fr) 2013-01-11
UY30642A1 (es) 2008-05-31
HRP20110759T1 (hr) 2011-11-30
CA2660166A1 (fr) 2008-04-24
KR20090064571A (ko) 2009-06-19
TW200821310A (en) 2008-05-16
MX2009003283A (es) 2009-04-08
CL2007002934A1 (es) 2008-05-30
DK2094699T3 (da) 2011-11-07
PL2094699T3 (pl) 2011-12-30
CO6160310A2 (es) 2010-05-20
US8314121B2 (en) 2012-11-20
EP2094699B1 (fr) 2011-07-20
FR2907120A1 (fr) 2008-04-18
RS51985B (sr) 2012-02-29
WO2008046982A3 (fr) 2008-06-19
AU2007311833B2 (en) 2013-05-02
JP2010505922A (ja) 2010-02-25
SI2094699T1 (sl) 2011-11-30
BRPI0719790A2 (pt) 2014-11-25
AU2007311833A1 (en) 2008-04-24
PT2094699E (pt) 2011-10-24

Similar Documents

Publication Publication Date Title
NO20091486L (no) Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
PH12022550156A1 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20082975L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20071073L (no) Heterocykel-substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
CY1114906T1 (el) Νεα παραγωγα 6-τριαζολοπυριδαζινο-σουλφανυλο βενζοθειαζολης και βενζιμιδαζολης, η διαδικασια της παρασκευης τους, η εφαρμογη τους ως φαρμακα, φαρμακευτικες συνθεσεις και νεα χρηση κυριως ως αναστολεις του μετ
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
PL378136A1 (pl) Pirymidyny i triazyny hamujące replikacją wirusa HIV
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
NO20076006L (no) Acetylenderivater
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
NO20055977L (no) Nye benzimidazolderivater
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
NO20064705L (no) Nye farmasoytiske preparater omfattende agonister av tyroidreseptoren
NO20070157L (no) Substituerte diketopiperaziner som oksytocinantagonister
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA201000340A1 (ru) Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application